Bill Status of HB3268 101st General Assembly
Short Description: MEDICAID-DRUGS-RARE DISEASES
Rep. Sara Feigenholtz
| 1/13/2021||House||Session Sine Die|
Statutes Amended In Order of Appearance
Synopsis As Introduced
Amends the Illinois Public Aid Code. Provides that the Department of Healthcare and Family Services shall not make recommendations or determinations that are more restrictive than federal labeling requirements by the U.S. Food and Drug Administration when making coverage recommendations or determinations affecting medical assistance recipients' access to (1) drugs and biological products for rare diseases and (2) drugs and biological products that are genetically targeted therapies. Requires the Department to implement an open and transparent process that includes clear guidelines for open public comment for the review and study of those drugs and biological products for rare diseases and those that are genetically targeted therapies. Requires the Illinois Drug and Therapeutics Advisory Board (Board) to develop and maintain a list of external experts who (i) possess scientific or medical training with respect to one or more rare diseases and (ii) are qualified to provide advice on rare disease issues and specified topics, including the impact of particular coverage, utilization management, and other relevant drug access policies. Requires the Department to adopt rules to ensure that any provisions of the Illinois Title XIX State Plan that affect medical assistance recipients' access to drugs and biological products for rare diseases are available to the public in a user-friendly and searchable format. Prohibits the Department from disclosing any confidential commercial or trade secret information of a drug manufacturer. Provides that the Board shall not be subject to the 6-month review moratorium for new drugs and shall review new drugs and biological products for rare diseases at the next regularly scheduled meeting. Effective immediately.